Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice

J Psychiatr Res. 2016 Nov:82:50-7. doi: 10.1016/j.jpsychires.2016.07.004. Epub 2016 Jul 7.

Abstract

Atorvastatin is a cholesterol-lowering statin that has been shown to exert several pleiotropic effects in the nervous system as a neuroprotective and antidepressant-like agent. Antidepressant-like effect of atorvastatin in mice is mediated by glutamatergic and serotoninergic receptors, although the precise intracellular signaling pathways involved are unknown. PI3K/Akt/GSK-3β/mTOR signaling pathway has been associated to neurobiology of depression and seems to be modulated by some pharmacological antidepressant strategies. The present study investigated the participation of the PI3K/Akt/GSK-3β/mTOR signaling pathway in the antidepressant-like effect of an acute atorvastatin treatment in mice. Atorvastatin sub-effective (0.01 mg/kg) or effective (0.1 mg/kg) doses in the tail suspension test (TST) was administered orally alone or in combination with PI3K, GSK-3β or mTOR inhibitors. The administration of PI3K inhibitor, LY294002 (10 nmol/site, i.c.v) completely prevented the antidepressant-like effect of atorvastatin (0.1 mg/kg, p.o.). The participation of GSK-3β in the antidepressant-like effect of atorvastatin was demonstrated by co-administration of a sub-effective dose of atorvastatin (0.01 mg/kg, p.o.) with AR-A014418 (0.01 μg/site, i.c.v., a selective GSK-3β inhibitor) or with lithium chloride (10 mg/kg, p.o., a non-selective GSK-3β inhibitor). The mTOR inhibitor, rapamycin (0.2 nmol/site, i.c.v.) was also able to prevent atorvastatin (0.1 mg/kg, p.o.) antidepressant-like effect. These behavioral findings were supported by neurochemical observations, as atorvastatin treatment increased the immunocontent of the phosphorylated isoforms of Akt, GSK-3β and mTOR in the hippocampus of mice. Taken together, our results suggest an involvement of the PI3K/Akt/GSK-3β/mTOR signaling pathway in the antidepressant-like effect of atorvastatin in mice.

Keywords: Antidepressant-like; Atorvastatin; GSK-3β; PI3K/Akt; Tail suspension test; mTOR.

MeSH terms

  • Analysis of Variance
  • Animals
  • Antidepressive Agents / therapeutic use*
  • Atorvastatin / therapeutic use*
  • Depression / drug therapy*
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Exploratory Behavior / drug effects
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hindlimb Suspension / methods
  • Immunosuppressive Agents / pharmacology
  • Male
  • Mice
  • Oncogene Protein v-akt / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Signal Transduction / drug effects*
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / metabolism*
  • Time Factors

Substances

  • Antidepressive Agents
  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Atorvastatin
  • mTOR protein, mouse
  • Glycogen Synthase Kinase 3 beta
  • Oncogene Protein v-akt
  • TOR Serine-Threonine Kinases
  • Sirolimus